Galmed Pharmaceuticals Ltd., a US-listed biopharmaceutical company, has announced a new digital asset management strategy, committing $10 million to digital asset investments. This allocation represents approximately 50% of the company's current cash reserves. To oversee these investments, Galmed has formed a cryptocurrency committee tasked with evaluating and managing cryptocurrency-related activities. The strategy will encompass digital asset portfolio rebalancing, participation in liquidity provision, staking income, and risk hedging. To facilitate this initiative, Galmed has signed a letter of intent with Tectona, a cryptocurrency asset management service provider, which will offer consulting and operational support.